CELG News and Press, Celgene Corporation From 08/13/19

Daniel Loeb's Third Point hedge fund says it cut its stake in United Technologies ( UTX +1% ), becoming the second activist hedge fund to sell shares following the merger announcement with Raytheon. More news on: United Technologies Corporation, Tradeweb Markets Inc., American Express ...

Introduction I've only had time to do three Q2 articles on biotechs, including Edwards ( EW ) in that category. In this article, I'll therefore present some comments on stocks which I have not written about in a few months or longer, as well a brief update on my largest biotech holding, Merc...

This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 08/09/2019. Please visit our Tracking David Abrams’ Abrams Capital Management ...

As the Celgene ( CELG ) acquisition heads towards closure, investors need to position themselves for owning shares in the new Bristol-Myers Squibb ( BMY ). The cash and stock transaction positions the long-term value of the merger in owning BMY stock, requiring investors to have a plan f...

Athenex ( ATNX -29.9% ) slumps on more than triple normal volume following its release of topline data from a Phase 3 clinical trial evaluating oral paclitaxel (Oraxol) compared to the intravenous formulation [Celgene's ( CELG -0.1% ) Abraxane] in patients with metastatic breast canc...

Merger activity decreased last week with three new deals announced and ten pending deals closing. Deal Statistics: New Deals: The acquisition of Genomic Health ([[GHDX]]) by Exact Sciences Corporation ([[EXAS]]) for $2.8 billion in a cash-plus-stock deal. Under the terms of the ...

Disneyland will never be completed. It will continue to grow as long as there is imagination left in the world." - Walt Disney For the most part, the second quarter saw a continuation of the first quarter's positive performance across many asset classes. This furthered a reversal o...

It's fairly rare that I pound the table for a specific stock because I'm happy to acknowledge that the market is unpredictable, and there are no sure things in the equity space. However, from time to time I see value that is so compelling that I can't help but hype up a potential investment op...

Jounce Therapeutics ( JNCE ) established an updated deal with its partner Celgene ( CELG ). The new deal consists of a total amount of $530 million in potential payments, but it replaces an old deal established back in 2016 worth a potential $2.6 billion. Still, it is good to see tha...

The following slide deck was published by Celgene Corporation in conjunction with their 2019 Q2 earnings Read more ...